PT84427B - Processo para a producao de interferoes hibridos uteis como agentes terapeuticos e como intermediarios para a producao de anticorpos bem como de composicoes farmaceuticas que os contem - Google Patents

Processo para a producao de interferoes hibridos uteis como agentes terapeuticos e como intermediarios para a producao de anticorpos bem como de composicoes farmaceuticas que os contem

Info

Publication number
PT84427B
PT84427B PT84427A PT8442787A PT84427B PT 84427 B PT84427 B PT 84427B PT 84427 A PT84427 A PT 84427A PT 8442787 A PT8442787 A PT 8442787A PT 84427 B PT84427 B PT 84427B
Authority
PT
Portugal
Prior art keywords
novel
interferons
production
hybrid
omega
Prior art date
Application number
PT84427A
Other languages
English (en)
Other versions
PT84427A (de
Inventor
Gerhard Bodo
Ingrid Maurer-Fogy
Rudolf Hauptmann
Gunther Adolf
Edgar Falkner
Peter Swetly
Peter Meindl
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PT84427A publication Critical patent/PT84427A/pt
Publication of PT84427B publication Critical patent/PT84427B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
PT84427A 1986-03-10 1987-03-09 Processo para a producao de interferoes hibridos uteis como agentes terapeuticos e como intermediarios para a producao de anticorpos bem como de composicoes farmaceuticas que os contem PT84427B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863607835 DE3607835A1 (de) 1986-03-10 1986-03-10 Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
PT84427A PT84427A (de) 1987-04-01
PT84427B true PT84427B (pt) 1989-10-04

Family

ID=6295926

Family Applications (1)

Application Number Title Priority Date Filing Date
PT84427A PT84427B (pt) 1986-03-10 1987-03-09 Processo para a producao de interferoes hibridos uteis como agentes terapeuticos e como intermediarios para a producao de anticorpos bem como de composicoes farmaceuticas que os contem

Country Status (21)

Country Link
US (1) US4917887A (pt)
EP (1) EP0236920B1 (pt)
JP (1) JPS62282595A (pt)
KR (1) KR950008191B1 (pt)
AT (1) ATE81671T1 (pt)
AU (1) AU600702B2 (pt)
DD (2) DD266118A5 (pt)
DE (2) DE3607835A1 (pt)
DK (1) DK120387A (pt)
ES (1) ES2052502T3 (pt)
FI (2) FI871012A (pt)
GR (1) GR3006844T3 (pt)
HU (1) HU206896B (pt)
IE (2) IE60573B1 (pt)
IL (1) IL81832A0 (pt)
NO (1) NO870967L (pt)
NZ (1) NZ219549A (pt)
PH (1) PH27060A (pt)
PT (1) PT84427B (pt)
SU (1) SU1604164A3 (pt)
ZA (1) ZA871679B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633323A1 (de) * 1986-10-01 1988-04-07 Boehringer Ingelheim Int Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega
DE3642096A1 (de) * 1986-12-10 1988-06-16 Boehringer Ingelheim Int Pferde-(gamma)-interferon
AT389318B (de) * 1987-10-22 1989-11-27 Boehringer Ingelheim Int Neue hybridomzellinien, welche neue monoklonale antikoerper gegen ifn-omega produzieren, verfahren zu ihrer herstellung und die verwendung der neuen monoklonalen antikoerper zur reinigung sowie zum nachweis von ifn-omega
US5000943A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Canine biscuits containing an inorganic pyrophosphate
US5047231A (en) * 1989-05-30 1991-09-10 Nabisco Brands, Inc. Raw hide containing an inorganic pyrophosphate
US5000940A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Devices, compositions and the like having or containing an inorganic pyrophosphate
US5000973A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Nutritionally-balanced canine biscuits containing an inorganic pyrophosphate
US5015485A (en) * 1989-05-30 1991-05-14 Nabisco Brands, Inc. Dog biscuits having a coating containing an inorganic pyrophosphate
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
EP1987845B1 (en) 1997-11-20 2012-03-21 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor.
ES2378977T3 (es) * 1998-03-13 2012-04-19 Brown University Research Foundation Isoforma del canal de calcio del tipo N humano y usos de la misma
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
AU2587002A (en) * 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
CA2454860A1 (en) * 2001-08-12 2003-02-27 Pepgen Corporation Hybrid interferon/interferon tau proteins, compositions and methods of use
ATE481135T1 (de) * 2001-11-09 2010-10-15 Intarcia Therapeutics Inc Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DK2020990T3 (da) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP5718925B2 (ja) 2009-09-28 2015-05-13 インターシア セラピューティクス，インコーポレイティド 実質的な定常状態薬物送達の迅速な確立及び／又は停止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN105358575B (zh) * 2013-03-15 2020-09-22 詹森生物科技公司 干扰素α和ω抗体拮抗剂
TWI713453B (zh) * 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77877C (fi) * 1979-04-20 1989-05-10 Technobiotic Ltd Foerfarande foer framstaellning och rening av human le-formig interferonprotein.
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
JPH064673B2 (ja) * 1980-11-10 1994-01-19 ゲネンテツク・インコ−ポレ−テツド ハイブリド型ヒト白血球インタフエロン
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
IT1167610B (it) * 1982-01-19 1987-05-13 Cetus Corp Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
AU1155083A (en) * 1982-01-19 1983-07-28 Cetus Corporation Multiclass hybrid interferons
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DE3409966A1 (de) * 1984-03-19 1985-09-26 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-gammainterferon und mittel zur durchfuehrung dieses verfahrens
DE3428370A1 (de) * 1984-08-01 1986-02-13 Boehringer Ingelheim International GmbH, 6507 Ingelheim Interferon, genetische sequenzen, die hierfuer codieren, und diese produzierende organismen
EP0170204B1 (de) * 1984-08-01 1991-09-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
DE3574145D1 (en) * 1984-08-27 1989-12-14 Genentech Inc Novel, distinct family of human leukocyte interferons, compositions containing them, methods for their production, and dna and transfected hosts therefor
EP0173935A1 (en) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
DE3685996T2 (de) * 1985-06-11 1993-01-14 Ciba Geigy Ag Hybrid-interferone.
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators

Also Published As

Publication number Publication date
FI871012A0 (fi) 1987-03-09
IE60573B1 (en) 1994-07-27
PT84427A (de) 1987-04-01
IE940131L (en) 1987-09-10
DK120387D0 (da) 1987-03-09
NZ219549A (en) 1990-07-26
EP0236920A3 (en) 1988-03-02
JPS62282595A (ja) 1987-12-08
DE3782259D1 (de) 1992-11-26
FI871012A (fi) 1987-09-11
HUT44074A (en) 1988-01-28
KR950008191B1 (ko) 1995-07-26
FI925631A0 (fi) 1992-12-11
ZA871679B (en) 1988-11-30
DD276493A5 (de) 1990-02-28
ES2052502T3 (es) 1994-07-16
PH27060A (en) 1993-02-01
DK120387A (da) 1987-09-11
ATE81671T1 (de) 1992-11-15
KR870009020A (ko) 1987-10-22
IL81832A0 (en) 1987-10-20
SU1604164A3 (ru) 1990-10-30
EP0236920A2 (de) 1987-09-16
US4917887A (en) 1990-04-17
IE870591L (en) 1987-09-10
FI925631A (fi) 1992-12-11
DD266118A5 (de) 1989-03-22
AU6978687A (en) 1987-09-17
DE3607835A1 (de) 1987-09-24
NO870967D0 (no) 1987-03-09
EP0236920B1 (de) 1992-10-21
NO870967L (no) 1987-09-11
HU206896B (en) 1993-01-28
GR3006844T3 (pt) 1993-06-30
AU600702B2 (en) 1990-08-23

Similar Documents

Publication Publication Date Title
PT84427B (pt) Processo para a producao de interferoes hibridos uteis como agentes terapeuticos e como intermediarios para a producao de anticorpos bem como de composicoes farmaceuticas que os contem
ES521418A0 (es) Procedimiento para la preparacion de proteinas funcionales de uroquinasa humana.
DE68924162D1 (de) Stressproteine und verwendungen dafür.
ES8201827A1 (es) Procedimiento para pasteurizar una composicion que contiene una proteina termicamente sensible y terapeuticamente activa
IT1179635B (it) Composizione e preparato per la somministrazione di medicamenti per via cutanea
FI864427A0 (fi) Menetelmä polypeptidin valmistamiseksi, joka on komplementaarinen ainakin osalle alkuperäistä peptidiä tai proteiinia, ja komplementaarisen polypeptidin käyttö
NZ209590A (en) Gamma interferon analogue, preparation and pharmaceutical composition
ES545052A0 (es) Un procedimiento para producir un derivado de un polipeptido de interferon-gamma-humano
PT91750A (pt) Processo para a preparacao de factor de crescimento de celulas t auxiliares
FI953525A (fi) Kemiallinen syntetointimenetelmä fibronektiiniä sitovan proteiinin tai polypeptidin valmistamiseksi
Hirofuji et al. Characterization of monoclonal antibody specific for human type II collagen: possible implication in collagen-induced arthritis.
DK102892D0 (da) Purin-derivater, farmaceutisk praeparat omfattende forbindelserne samt forbindelser til brug som mellemprodukter
FI93843B (fi) Menetelmä angiogeenisen tekijän tuottamiseksi
ES534859A0 (es) Procedimiento para la obtencion de derivados de 1-(4'-alquilsulfonilfenil)-2-amino-1,3-propandiol n-substituidos
Bečka et al. Some properties of the goat placental lactogen
SE8504371L (sv) Alkoholiska drycker med hog proteinhalt och forfarande for framstellning derav
NO177536C (no) HIV-1-relaterte polypeptider, preparat som omfatter en blanding med minst to polypeptider, samt diagnostisk system og anvendelse av et polypeptid for måling av anti-HIV-1-antistoffer
IL72986A0 (en) Homogenous immune interferon fragment,its manufacture and pharmaceutical compositions containing it
LIU et al. Preparation of refined antimeasles gamma globulin from immunized goats and pigs
FI934079A (fi) Menetelmä fuusioproteiinin valmistamiseksi
IT8119508A0 (it) Derivato dell'acido acetilsalicilico ad attivita'terapeutica, procedimento per lasua preparazione e relative composizioni farmaceutiche.

Legal Events

Date Code Title Description
MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19950930